Format

Send to

Choose Destination
See comment in PubMed Commons below
Hum Pathol. 2016 Jan;47(1):78-84. doi: 10.1016/j.humpath.2015.09.006. Epub 2015 Sep 25.

Prognostic significance of PD-L1 and PD-L2 in breast cancer.

Author information

1
Department of Obstetrics and Gynecology, Women's Hospital (CAISM), Faculty of Medical Sciences, State University of Campinas UNICAMP, 13083-970, Campinas, SP, Brazil. Electronic address: mzbaptista@gmail.com.
2
Department of Obstetrics and Gynecology, Women's Hospital (CAISM), Faculty of Medical Sciences, State University of Campinas UNICAMP, 13083-970, Campinas, SP, Brazil. Electronic address: sarian@unicamp.br.
3
Department of Obstetrics and Gynecology, Women's Hospital (CAISM), Faculty of Medical Sciences, State University of Campinas UNICAMP, 13083-970, Campinas, SP, Brazil. Electronic address: sophie.derchain@gmail.com.
4
Laboratory of Investigative and Molecular Pathology (LAPE), Women's Hospital (CAISM), Faculty of Medical Sciences, State University of Campinas UNICAMP, 13083-970, Campinas, SP, Brazil. Electronic address: glaujv@fcm.unicamp.br.
5
Laboratory of Investigative and Molecular Pathology (LAPE), Women's Hospital (CAISM), Faculty of Medical Sciences, State University of Campinas UNICAMP, 13083-970, Campinas, SP, Brazil. Electronic address: vassallomeister@gmail.com.

Abstract

PD-L1 and PD-L2 constitute an important antitumor immune response. In breast cancer, their prognostic value is still to be defined. In this study, we investigate the correlation between PD-L1 and PD-L2 protein expressions with clinical and pathologic features and disease-free survival and overall survival. To assess PD-L1 and PD-L2 expressions, we conducted immunohistochemistry studies using a breast cancer tissue microarray encompassing a total of 192 breast cancer cases, stages I, II, and III, with detailed clinical and outcome data. PD-L1 expression was present in 56.6% (107/189), and PD-L2 expression was identified in 50.8% (97/191) of breast cancer cases. Younger age at diagnosis, lymph node positivity, negative estrogen receptor, and recurrence at distant sites were all associated with both PD-L1 and PD-L2 expressions. The presence of larger tumors was associated only with PD-L1 expression. In our study, PD-L1 expression was significantly associated with better overall survival (P = .04) in breast cancer patients. Despite its association with poor clinical and pathologic features, PD-L1 expression emerges as a positive prognostic biomarker in breast cancer. This survival result might be due to the presence of a strong antitumor immune response leading to PD-L1 expression.

KEYWORDS:

Biomarker; Breast cancer; PD-L1; PD-L2; Prognosis; Survival

PMID:
26541326
DOI:
10.1016/j.humpath.2015.09.006
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center